Ampyra Package Insert

Pharmacy Medical Necessity Guidelines: Ampyra (dalfampridine)
Ampyra® (dalfampridine) experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions. ... Document Retrieval

AMPYRA® (dalfampridine) Extended Release Oral Tablet ...
Ampyra® package insert revised by manufacturer 01-2013, reviewed on 11/16/2013 Ampyra® package insert revised by manufacturer 01-2014, reviewed on 09/04/2014 Ampyra® package insert revised by manufacturer 12-2014, reviewed on 10/13/2015, 09/27/2016 Ampyra® Medication Guide Ampyra® Risk Evaluation and Mitigation Strategy (REMS) ... Get Document

Dalfampridine (Ampyra
On ADLs or IADLs was provided. In deciding whether to treat any given patient with dalfampridine (Ampyra), potential benefit must be weighed against possible harms associated with treatment. References 1. Dalfampridine (Ampyra) extended-release tablets [package insert]. Hawthorne, NY: Acorda Therapeutics, Inc.; July 2012. 2. ... View Document

Jakafi Prescribing Information
Jakafi is a kinase inhibitor indicated for treatment of patients with: • intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. ... Read More

Ampyra Clinical Edit June 30, 2011 MO HealthNet
Frequency of relapses and slow disease progression. Ampyra is a broad-spectrum potassium channel blocker, and the first MS medication thought to enhance signal conduction in the nerves by blocking some of the potassium leaks. This medication is indicated as a treatment to improve walking in people with MS, demonstrated by an increase in walking ... Access Document

New Drug Update - Ampyra
Place in Therapy: Dalfampridine (Ampyra) offers the first oral medication to improve walking in patients with MS. Improvements in walking speed occured in the minority of studied patients and on average appear to be modest. ... View Doc

WARNINGS AND PRECAUTIONS AMPYRA Can Cause Seizures; The Risk ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE AMPYRA is indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). ... Doc Retrieval

REGLAN Injection (metoclopramide Injection, USP)
REGLAN Injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy . REGLAN Injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. ... Retrieve Document

Ampyra (dalfampridine)
Ampyra ® (dalfampridine) INDICATION:1 “AMPYRA (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.” Ampyra [package insert]. Ardsley, NY; Acorda Therapeutics, Inc., Jan 2014. ... Retrieve Full Source

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFIENTsafely and effectively. See full prescribing information for EFFIENT. EFFIENT(prasugrel) tablets, for oral use Initial U.S. Approval: 2009 WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. ... Fetch This Document

Prior Authorization Approval Criteria
• Ampyra ® [package insert], Ardsley, NY: Acorda; 2017. • National Institute for Health and Care Excellence (2014) Multiple sclerosis in adults: management. Clinical Guideline CG186. London: National Institute for Health and Care Excellence. ... Fetch Full Source

STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN ...
Prior authorization requests for Ampyra will be approved if the following criteria are met: 1. Diagnosis of multiple sclerosis; AND Ampyra package insert, Acorda Therapeutics, 2010/01 Reviewed and Approved DUR Board 05/05/2010. Healt BUREAU FOR MEDICAL SERVICES . ... Fetch Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMITIZA safely and effectively. See full prescribing information ... Retrieve Document

Therapeutic Class Overview Potassium Channel Blockers
[package insert]. Ardsley (NY): Acorda Therapeutics, Inc.; 2012 Aug. 2. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis [press release on the Internet]. ... Read Full Source

HIGHLIGHTS OF PRESCRIBING INFORMATION Observe Patients During ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TYSABRI safely and effectively. See full prescribing information for TYSABRI. ... Read Content

MEDICATION GUIDE AMPYRA® (am-PEER-ah) (dalfampridine ...
AMPYRA is a prescription medicine used to help improve walking in adults with multiple sclerosis (MS). This was shown by an increase in walking speed. It is not known if AMPYRA is safe or effective in children less than 18 years of age. ... Retrieve Content

Pharmacy Medical Policy Ampyra™ (dalfampridine)
We may cover Ampyra™ when the above criteria is met and with previous use of dalfampridine. Continuation: Documentation of at least 20% improvement in timed 25-Foot Walk test (timed 25-Foot Walk (T25FW) test) from baseline or improvement in EDSS scores If approved, authorization length valid for additional 1 year. ... Get Doc